Enterprise AI adoption looks strong, but real ROI lags. Why coordination theater, shadow IT and stalled redesign are distorting compounding value.

A look at the biologics, gene therapies, and vaccines most likely to reshape care —and manufacturing—in the year ahead.

Data is the life-blood of physical AI. Collecting real-life data is expensive. Generative AI and diffusion to create ...

More than two dozen contributors to the manual criticized the deletion of a chapter on climate science by the Federal Judicial Center. By Karen Zraick Leticia Carvalho heads a global authority that’s ...

A better way to drive growth and profitability by Scott Magids, Alan Zorfas and Daniel Leemon When companies connect with customers’ emotions, the payoff can be huge. Consider these examples: After a ...

Don’t start with moon shots. by Thomas H. Davenport and Rajeev Ronanki In 2013, the MD Anderson Cancer Center launched a “moon shot” project: diagnose and recommend treatment plans for certain forms ...

Despite a definitive pullback among popular quantum computing stocks, they seem to be picking up where they left off in 2025, with the benchmark Defiance Quantum ETF (ticker: QTUM) up 6% year to date ...